HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism

Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia

(2017) Harilal Patel et al.   XENOBIOTICA

A Novel Hypoxia-Inducible Factor−Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial

(2016) Richard A. Brigandi et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

(2016) Robert Provenzano et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects

(2016) Tadao Akizawa et al.   AMERICAN JOURNAL OF NEPHROLOGY

Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension

(2016) Andrew J. Bryant et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Prolyl-4-hydroxylase 2 and 3 coregulate murine erythropoietin in brain pericytes

(2016) Andres A. Urrutia et al.   BLOOD

Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2αCLINICAL PERSPECTIVE

(2016) Zhiyu Dai et al.   CIRCULATION

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

(2016) R. Provenzano et al.   Clinical Journal of the American Society of Nephrology

Inflammation regulates fibroblast growth factor 23 production

(2016) Connor Francis et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Distinct subpopulations of FOXD1 stroma-derived cells regulate renal erythropoietin

(2016) Hanako Kobayashi et al.   JOURNAL OF CLINICAL INVESTIGATION

Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease

(2016) Pablo E. Pergola et al.   KIDNEY INTERNATIONAL

Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification

(2016) Sophie Mokas et al.   KIDNEY INTERNATIONAL

The Endothelial Prolyl-4-Hydroxylase Domain 2/Hypoxia-Inducible Factor 2 Axis Regulates Pulmonary Artery Pressure in Mice

(2016) Pinelopi P. Kapitsinou et al.   MOLECULAR AND CELLULAR BIOLOGY

SO036MOLIDUSTAT INCREASES HAEMOGLOBIN IN ERYTHROPOIESIS STIMULATING AGENTS (ESA)-NAIVE ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS (CKD-ND)

(2016) Iain C. Macdougall et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

HIF2α–arginase axis is essential for the development of pulmonary hypertension

(2016) Andrew S. Cowburn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats

(2015) Terrance D Barrett et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects

(2015) Katsutoshi Hara et al.   Drug Metabolism and Pharmacokinetics

Erythropoietin Synthesis in Renal Myofibroblasts Is Restored by Activation of Hypoxia Signaling

(2015) T. Souma et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia

(2015) L. Holdstock et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients

(2015) A. Besarab et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Anaemia in kidney disease: harnessing hypoxia responses for therapy

(2015) Mark J. Koury et al.   Nature Reviews Nephrology

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

(2015) Anatole Besarab et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

The ESA scenario gets complex: from biosimilar epoetins to activin traps

(2014) W. Jelkmann   NEPHROLOGY DIALYSIS TRANSPLANTATION

Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects

(2014) Ingo Flamme et al.   PLoS One

Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease

(2013) Peter A. McCullough et al.   AMERICAN JOURNAL OF NEPHROLOGY

Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology

(2013) Gregg L. Semenza   Annual Review of Pathology-Mechanisms of Disease

IRP1 regulates erythropoiesis and systemic iron homeostasis by controlling HIF2  mRNA translation

(2013) N. Wilkinson et al.   BLOOD

Regulation of erythropoiesis by hypoxia-inducible factors

(2013) Volker H. Haase   BLOOD REVIEWS

The IRP1-HIF-2α Axis Coordinates Iron and Oxygen Sensing with Erythropoiesis and Iron Absorption

(2013) Sheila A. Anderson et al.   Cell Metabolism

Deletion of Iron Regulatory Protein 1 Causes Polycythemia and Pulmonary Hypertension in Mice through Translational Derepression of HIF2α

(2013) Manik C. Ghosh et al.   Cell Metabolism

Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis

(2013) Maria Lönnberg et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Mechanisms of Hypoxia Responses in Renal Tissue

(2013) V. H. Haase   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Pulmonary Hypertension in CKD

(2012) Davide Bolignano et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Regulation of hypoxia-inducible factor in kidney disease

(2012) Masaomi Nangaku et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Renal cancer: Oxygen meets metabolism

(2012) Volker H. Haase   EXPERIMENTAL CELL RESEARCH

Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis

(2012) Qingdu Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

Novel links between HIFs, type 2 diabetes, and metabolic syndrome

(2012) Christian M. Girgis et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

The HIF Pathway and Erythrocytosis

(2011) Frank S. Lee et al.   Annual Review of Pathology-Mechanisms of Disease

High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq

(2011) J. Schodel et al.   BLOOD

Deletion of HIF-2  in the enterocytes decreases the severity of tissue iron loading in hepcidin knockout mice

(2011) M. Mastrogiannaki et al.   BLOOD

Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression

(2011) V. R. Gordeuk et al.   BLOOD

Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2α gain-of-function mutation

(2011) Federico Formenti et al.   FASEB JOURNAL

Hypoxia-Inducible Factor-2α Mediates the Adaptive Increase of Intestinal Ferroportin During Iron Deficiency in Mice

(2011) Matthew Taylor et al.   GASTROENTEROLOGY

Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis

(2011) M. Mastrogiannaki et al.   HAEMATOLOGICA

Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia

(2010) P. P. Kapitsinou et al.   BLOOD

The von Hippel–Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice

(2010) Michele M. Hickey et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD

(2010) W. M. Bernhardt et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Anemia management in chronic kidney disease

(2010) Steven Fishbane et al.   KIDNEY INTERNATIONAL

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

(2010) Scott D. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reactivation of Hepatic EPO Synthesis in Mice After PHD Loss

(2010) Y. A. Minamishima et al.   SCIENCE

What Is So Bad About a Hemoglobin Level of 12 to 13 g/dL for Chronic Kidney Disease Patients Anyway?

(2009) Anatole Besarab et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

Intestinal Hypoxia-Inducible Transcription Factors Are Essential for Iron Absorption following Iron Deficiency

(2009) Yatrik M. Shah et al.   Cell Metabolism

Hepcidin--A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease

(2009) J. Zaritsky et al.   Clinical Journal of the American Society of Nephrology

HIF-2α, but not HIF-1α, promotes iron absorption in mice

(2009) Maria Mastrogiannaki et al.   JOURNAL OF CLINICAL INVESTIGATION

Hypoxia-Inducible Factor 2 Regulates Hepatic Lipid Metabolism

(2009) E. B. Rankin et al.   MOLECULAR AND CELLULAR BIOLOGY

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

(2009) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The microenvironment for erythropoiesis is regulated by HIF-2  through VCAM-1 in endothelial cells

(2008) T. Yamashita et al.   BLOOD

Repression via the GATA box is essential for tissue-specific erythropoietin gene expression

(2008) N. Obara et al.   BLOOD

Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes

(2008) Lynda A. Szczech et al.   KIDNEY INTERNATIONAL

Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway

(2008) William G. Kaelin et al.   MOLECULAR CELL

Expanding chemical biology of 2-oxoglutarate oxygenases

(2008) Christoph Loenarz et al.   Nature Chemical Biology

Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease

(2008) N. D. Vaziri et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION